Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Repeated Dose Study of Dotinurad in Healthy Males
NCT02348333Phase 1Completed
- Sponsor
- Fuji Yakuhin
- Start
- Sep 2013
- Primary completion
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial in hyperuricemia and gout comparing FYU-981 with Placebo (2 arms). Primary endpoints: Maximum plasma concentration at 7 days, Minimum plasma concentration at 7 days and 8 more. Started Sep 2013; status: completed.
02
Drugs
dotinurad
03
Conditions
hyperuricemiagout
Beyond the preview
Go deeper on NCT02348333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02348333.